MYC and hepatocellular carcinoma: To study MYC-dependent metabolism in HCC, we and others have utilized the MYC-driven LAP-tTA/TRE-MYC (LT2-MYC) transgenic mouse model of liver cancer initially developed in the lab of J.M. Bishop, which allows for MYC overexpression specifically in hepatocytes in the absence of doxycycline (Shachaf et al., 2004).